Pharma and BioTech Daily — August 26, 2025

Episode: AbbVie Acquires Gilgamesh, IPO Stalemate Ends, Oral Obesity Therapies Disappoint

Main Theme & Purpose

This episode provides a concise roundup of the most significant developments in pharma and biotech, focusing on high-impact acquisitions, FDA regulatory actions, the status of key IPOs, disappointments in obesity therapy pipelines, and updates in RNA and gene therapies.

Key Discussion Points & Insights

1. AbbVie Acquires Gilgamesh Pharmaceuticals

• Acquisition Overview:
  • AbbVie announced the acquisition of Gilgamesh Pharmaceuticals for $1.2 billion.
  • The intent is to enhance AbbVie’s presence in neurology and depression treatments.
  • This move comes on the heels of AbbVie’s failed emreclodine program for schizophrenia.
• Host’s Insight:
  • "Abbvie has acquired gilgamesh pharmaceuticals for $1.2 billion, focusing on neurology and depression treatments. This move follows AbbVie's previous failure with emreclodine in schizophrenia treatment." (00:07)
  • Suggests AbbVie is doubling down on neuropsychiatry despite setbacks.

2. Biotech IPO Market Awakening

• Industry Stalemate Lifting:
  • After a prolonged lull in biotech IPOs, momentum is returning.
  • LB Pharma is planning a public offering to finance a Phase III-ready schizophrenia drug.
• Host’s Perspective:
  • "The biotech industry's IPO stalemate appears to be ending, with LB Pharma planning an IPO to fund a Phase three ready schizophrenia asset." (00:20)
  • Signals renewed investor confidence in late-stage assets.

3. Regulatory Setbacks

• FDA Removes Valneva’s Chikungunya Vaccine:
  • The FDA has withdrawn approval for Valneva’s Chikungunya vaccine due to safety concerns.
  • Reflects ongoing scrutiny of vaccine candidates.
• FDA Action Summary:
  • "The FDA has pulled Valneva's Chikungunya shot from the market due to safety concerns..." (00:27)

4. Oral Obesity Therapies Struggle

• Pipeline Disappointments:
  • Multiple oral obesity drugs failed to reach the market as expected.
  • Eli Lilly’s Orforglipron and Viking Therapeutics’ VK2735 delivered underwhelming trial results.
  • Focus now shifts to emerging market demand for accessible weight-loss solutions.
• Novo Nordisk Emerges as Leader:
  • Novo remains at the forefront of obesity therapy innovation.
• Market Implications:
  • Increased interest in affordable weight loss therapies for low and middle income nations.
• Quote Highlight:
  • "...the disappointment of oral obesity therapies is discussed with Novo emerging as a leader in the field. Trials for Eli Lilly's Orforglipron and Viking Therapeutics VK2735 were underwhelming..." (00:39)

5. Advances in RNA Therapies

• Arnatar’s Ambition:
  • Company is pushing the boundaries of RNA therapies, aiming for applications beyond gene silencing.
• Host’s Take:
  • "...Arnatar is working on advancing RNA therapies beyond silencing." (00:35)
  • Suggests a new wave of functional RNA drugs is on the horizon.

6. Capricor Therapeutics Challenges FDA Rejection

• Therapeutic Focus:
  • Capricor is disputing FDA’s denial of its genetic therapy for Duchenne Muscular Dystrophy (DMD)-related cardiomyopathy.
• Host on Regulatory Hurdles:
  • "Capricor Therapeutics plans to fight FDA rejection of its DMD cardiomyopathy treatment..." (00:53)

7. JAMA Study Counters Vaccine Committee Critiques

• Public Trust and Policy:
  • A new JAMA study provides evidence contradicting recent allegations of corruption in national vaccine advisory committees.
• Quote Highlight:
  • "...a study in JAMA contradicts claims of corruption in vaccine Advisory committees..." (00:57)

8. Oncology Updates

• Cell and Gene Therapy:
  • Continued developments in cancer cell and gene therapy were briefly noted, signaling ongoing innovation in the space.
• Host Wrap-Up:
  • "updates on cancer cell and gene therapy are also provided." (01:02)

Notable Quotes & Memorable Moments

• On the significance of AbbVie’s acquisition:
  • "This move follows AbbVie's previous failure with emreclodine in schizophrenia treatment." (00:12)
• On oral obesity therapy disappointments:
  • "Trials for Eli Lilly's Orforglipron and Viking Therapeutics VK2735 were underwhelming, leading to increased interest in weight loss pills in low and middle income countries." (00:41)

Timestamps for Important Segments

• AbbVie Acquires Gilgamesh: 00:07–00:15
• IPO Stalemate Ends: 00:20–00:25
• Valneva Chikungunya Vaccine Pulled: 00:27–00:34
• RNA Therapy Advances (Arnatar): 00:35–00:37
• Oral Obesity Therapies Disappoint: 00:38–00:45
• Capricor Therapeutics vs. FDA: 00:53–00:56
• Vaccine Committee Integrity (JAMA Study): 00:57–01:01
• Cancer Cell & Gene Therapy Updates: 01:02–01:06

Conclusion

This episode captures pivotal industry shifts, highlighting AbbVie’s ongoing commitment to neuropsychiatry, the returning vigor of biotech IPOs, regulatory hurdles facing innovators, shifting trends in obesity drug development, and fresh optimism for advanced therapies. The tone remains concise and informative, focusing sharply on news that shapes the future of pharma and biotech.

For feedback or topic suggestions, listeners are encouraged to reach out.